CD117 expression on blast cells in acute myeloid leukemia.

Goryainova, N. V.; Gordienko, A. I.; Кубарова, В.А.

doi:10.26641/2307-0404.2015.3.53688

Medicni Perspektivi (Medical Perspectives)

2015

DOI: 10.26641/2307-0404.2015.3.53688

|View full text |Cite

CD117 expression on blast cells in acute myeloid leukemia.

N. V. Goryainova¹,

A. I. Gordienko²,

В.А. Кубарова³

Abstract: Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol. 2011;29(32):4250-9. 13. Nicolini FE, Ibrahim AR, Soverini S, et al.The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

Expression Profile of Some Markers of Leukemic Stem Cells in Acute Myeloid Leukemia

Shlapatska,

Polishchuk,

Gluzman

2023

Oncology

View full text Add to dashboard Cite

Summary. Aim: identification of a potential pool of leukemic stem cells based on the combined expression of CD34, CD38 and CD117 in different acute myeloid leukemia (AML) subtypes. Object and methods: the studies were conducted on samples of bone marrow aspirates from 54 patients with newly diagnosed and untreated AML. The profile of the expression of surface antigens on leukemic (blast) cells of AML patients was studied by flow cytometry. Results: differences were found in the number of CD34+CD38–, CD34+CD38+, CD34–CD117+ and CD34+CD117+ cells, which can be leukemic stem cells (LSCs), among patients with different AML subtypes. The median percentage of CD34+CD38– cells in M2 AML (3.9%) and M3 AML (2.5%) is significantly lower than in M1 AML (11.3%) and M5 AML (13.0%), while the content of CD34+CD38+ cells is most represented in M2 AML and M5 AML. The analysis of the combined expression of CD34 and CD117 shows that M3 AML is more characterized by the presence of a population of CD34–CD117+ cells, while M1 AML and M5 AML are characterized by CD34+CD117+ blasts. Conclusion: in all studied AML subtypes, compartments of malignantly transformed cells, that potentially may be LSCs have been identified and are determined by the combined expression of CD34, CD38 and CD117. These studies are promising, since the definition of LSCs is the foundation for effective targeted therapy in patients with AML.

show abstract

Expression Profile of Some Markers of Leukemic Stem Cells in Acute Myeloid Leukemia

Shlapatska,

Polishchuk,

Gluzman

2023

Oncology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

CD117 expression on blast cells in acute myeloid leukemia.

Cited by 1 publication

References 1 publication

Expression Profile of Some Markers of Leukemic Stem Cells in Acute Myeloid Leukemia

Expression Profile of Some Markers of Leukemic Stem Cells in Acute Myeloid Leukemia

Contact Info

Product

Resources

About